Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.
AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.
Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch
Amgen has shelved its once-promising psoriasis drug. Should investors worry?
Investing for Beginners: How to Start in Biotech
Biotech can be tricky to learn, so we asked the experts to give their best advice to beginners. Here is what they said.